

Disclaimer


This presentation has been prepared by Avantium N.V. (the "Company"). For the purposes of this notice, the presentation that follows (the "Presentation") shall mean and include the slides that follow, the oral presentation of the slides by the Company, the question-andanswer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation.

Some of the statements in this Presentation constitute forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements relate to future events or the Company's future financial performance. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. In evaluating these statements, various risk factors should be taken into account. Risk factors may cause actual results to differ materially from any forward-looking statement. Although the Company believes that the expectations reflected in the forward looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company is under no duty to update any of the forward-looking statements after the date of this Presentation or to conform such statements to actual results.

The information contained in this Presentation is for information purposes only. The information does not constitute or form part of, and should not be construed as, an offer to sell or issue, or a solicitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction, and is not for publication or distribution in the US or to persons in the US (within the meaning of Regulation S under the US Securities Act of 1933 (the "Securities Act")), Canada, Japan, Australia or any other jurisdiction where such distribution or offer is unlawful. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of any securities in the United States. Subject to certain limited exceptions, neither this Presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the US, its territories or possessions. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.




DSM





Transaction overview

| Term sheet overview | | | | |
|---------------------------------------|---|--|--|--|
| lssuer | avantium | | | |
| Listing Venue | Euronext Amsterdam & Euronext Brussels | | | |
| Size and Price | Public offering and private placement of up to €45m Maximum subscription price set at €4.60 per new share. The maximum subscription price is indicative. The final offer price and the number of Offer Shares offered in the Offering will be determined following the Offering period on the basis of a book-building process | | | |
| Offering Structure | The Offering consists of a: Priority Allocation Offering open only to eligible existing institutional and retail shareholders (which excludes those in Restricted Jurisdictions as defined in the Prospectus) Retail Offering in the Netherlands to retail investors Private Placement to qualified investors in the EU, institutional investors outside the European Union and a limited number of other investors in member states of the EU in reliance on exemptions from Regulation 2017/1129. Offer Shares will only be offered and sold in offshore transactions outside the United States in reliance on Regulation S under the US Securities Act of 1933. | | | |
| Existing Shareholders' Commitments | Existing long-term shareholders of Avantium, funds managed by APG Asset Management N.V., investors represented by Wierda en Partners Vermogensbeheer B.V., Navitas B.V., Robeco Institutional Asset Management B.V. and other shareholders have irrevocably undertaken to subscribe for an aggregate amount of €12.2 million, or 27% of the Offering. | | | |
| Marketing Structure | Mix of physical/virtual meetings Active approach towards both retail and institutional investors | | | |
| Lock-up & Standstill | Company: 180 days Management: 180 days | | | |
| Timing | 6 April 2022: Launch 13 April 2022: End of Retail & Priority Allocation Offering Periods 14 April 2022: End of Private Placement Offering Period 15 April 2022: Announcement of the results of the Offering 19 April 2022: First day of trading on Euronext Amsterdam and Euronext Brussels 21 April 2022: Settlement | | | |
| Use of Proceeds | 60% to further develop plantMEG[™] technology and scale-up towards further commercialization via technology licensing 30% for general corporate purposes, working capital and overall funding 10% to further develop biorefinery and CO₂ based chemicals and polymers technologies and assess economic feasibility and scale-up towards further commercialization | | | |




Avantium at a glance: a pioneer in renewable chemistry



Increasing worldwide use of plastics causes major environmental challenges

Global plastics production will triple by 2050

Plastic production and waste cause major environmental problems



Avantium | Investor Presentation April 2022

Next generation consumers calling for action





85% of global respondents among millennials feel strongly that companies should help improve the environment

Governments putting regulatory targets & frameworks in place



"Single-use plastics are now forbidden in the EU when an affordable alternative exists"




"By 2025, all plastic packaging is 100% reusable, recyclable or compostable" Companies throughout the value chain are shifting towards sustainable and carbon neutral



"By 2025, all of our plastic packaging will be 100% reusable, recyclable or compostable to help build a circular economy for plastic"






Sources: Nova Institute

Fossil-based 360 Mt


40 Mt 10%

90%

Sustainable




Avantium's cutting-edge PEF led to numerous strategic collaborations & recent offtake agreements







Avantium's succesful trajectory towards growth











PEF is a 100% plant-based plastic made from FDCA and plantMEG


Avantium | Investor Presentation April 2022



Bio-based feedstock PEF is 100% plant-based

recycling only






plantMEG is a key drop-in ingredient for large end-markets

Avantium value proposition

plantMEG will provide brands with a sustainable & innovative ingredient








Addressing an extensive number of end-markets over time

| Today | Tomorrow | Longer-term |
|--|---|--|
| High-value applications | Value applications | Mainstream applications |
| Specialty bottles: • Multi-layer • Monolayer | PEF bottles to replace Glass bottles Aluminium cans | PEF bottles to replace • PET bottles (beverages, personal care) |
| Specialty films: • Barrier • Optical | Films & Fibers: • Technical fibers • Flexible films (shrink films and skin layer) | Other• Fiber – Apparel• Automotive• Thermoforming |



PEF has enhanced product performance



Source: European Bioplastocs; Company Assessment based on: Markus Schmidt et al, Properties of Whey-Protein-Coated Films and Laminates as Novel Recyclable Food Packaging Materials with Excellent Barrier Properties (International Journal of Polymer Science, Volume 2012), https://www.mgc.co.jp/eng/products/ac/nmxd6/barrier.html, http://asuka-platech.com/wp/wp-content/uploads/2013/12/BIOPBS.pdf

Note: (1) Barrier properties for 50µm film; (2) Water vapor barrier: WTR at (39 dC 85 %RH) [mL/(m2 · day)]; (3) Oxygen barrier: OTR (23, 0%RH) [mL/(m2 · day · atm)]



From technology development to commercialization



The world's first plant producing FDCA on a commercial scale



FDCA Flagship Plant secured financing breakdown


Funding sources



Funding uses



CAPEX: €115m



Grants (€27m):

- €20m PEFerence grant⁽¹⁾
- €7.5m grant from the National Programme Groningen

Third Party Equity (€30m):

- €20m equity from Groningen consortium
- €10 million equity from Worley
- Represents 22.6% of the Renewable Business equity

Avantium Equity (€45m):

- €45m investment by Avantium (increased from €35m)
- Represents 77.4% of the Renewable Business equity

avantium

CRONINCEN SEAR

Worley

Bio based Industries

GROElfonds


PEFerence

Debt Financing (€90m):

- Each bank has committed €15m
- Invest-NL, government backed Dutch impact investment fund, has committed €30m
- Interest consists of three components: cash interest, accrued interest and warrants



Successfully de-risked a cross the entire value chain



Note: (*) This project has received funding from the Bio-based Industries Joint Undertaking (JU) under the European Union's Horizon 2020 research and innovation program under grant agreement No744409. The JU receives support from the European Union's Horizon 2020 research and innovation program and the Bio-based Industries Consortium.

Avantium has a well-defined and scalable go-to-market strategy for PEF/FDCA

| Product characteristic s | Flagship Plant (5kt/a) In-house production €€€€ | Industrial Plant (100kt/a) | Industrial (>250kt/a) Licensing € | | |
|--|--|----------------------------|---|--|--|
| | Today | Tomorrow | Longer-term | | |
| Competitiv e positioning | High-value applications | Value applications | Mainstream applications | | |
| Initial focus on high-value applications with further volume growth to result in cost reduction, leading to a competitive offering across high volume end-markets | | | | | |

Avantium | Investor Presentation April 2022



Avantium tomorrow: further develop & commercialize its innovative technologies






Construction of its plantMEG Commercial Plant, leveraging on the succesful experience in FDCA



Success of FDCA strategy execution will accelerate plantMEG execution





Commercial


Operational

Technological

Key drivers supporting Avantium's market potential



Illustrative revenue and profitability model showcasing the large financial opportunity



Revenue & profitability mechanics

=

€67.5m-

€135m

Illustrative

annual

turnover

Avantium | Investor Presentation April 2022

=

€63m-

€126m

Use of proceeds from future capital raise

plantMEG:

Further develop plantMEG technology (technical validation, commercial & application validation) Scale-up towards further commercialization via technology licensing

avantium

€45m

Other technologies:

- Further develop biorefinery and CO2 based chemicals and polymers technologies
- Assess economic feasibility & scale-up towards further commercialization

Overall funding:

- Allowing positive cash balances for the following 3yrs
- Sufficient funding in conjunction with secured debt financing





Key milestones successfully achieved...


- Proven R&D and innovative technologies
- Successful technology testing
- Proven de-risking capacity for commercial production
- Blue-chip client partnerships
- Highly experienced management team



...Forming the foundation for commercialization

- ✓ Construct FDCA Flagship Plant
- Construct plantMEG Commercial Plant
- Commercial ramp-up via industrial licensing









Avantium: experienced leadership team

Education:

(Amsterdam)

Top Team Chemie

Management Team




Tom van Aken CEO (@Avantium since 2002)



Gert-Jan Gruter CTO (@Avantium since 2000)



Carmen Portocarero General Counsel (@Avantium since 2012)



Now: several advisory positions, such as **Bart Welten** CEO 1999-2002: Director Business development

(@Avantium since 2020)

1997-1999: Sales manager at DS



Bas Blom Managing Director Renewable Polymers (@Avantium since 2021)

Supervisory Board



Education:

Law (Leiden) and MBA (Boston)

Selected previous / other positions:

- Now: Supervisory Board Sanauin
- 2012-2019: CFO at Centrient Pharmaceuticals
- 2003-2012: CFO at DSM Resins
- 2002-2003: CEO at Kiadis Pharma




Steven Olivier Managing Director Catalysis (@Avantium since 2015)

- Edwin Moses, Chairman Former CEO Ablynx NV and Oxford Asymmetry International
- Margret Kleinsman CFO Agrifirm •
- Michelle Iou
- President Covestro Polycarbonates Business
- Cynthia Arnold
- Trudy Schoolenberg
- Nils Björkman
 - Pak Group

Former CTO Sun Chemical and Valspar

Held various senior management positions at Shell and AkzoNobel Worked for 33 years in various senior management positions at Tetra

Company strategy by business line



Announced commissioning year / run-rate capacity Busine Peers 3M market Produ SS cap. ranae ct **Before** (€m)⁽¹⁾ 2022 2023 2024 2025 2026 model FDCA plants [€130m -€185ml ndustrial plan PlantMEG avantium **Build & License** (>150kt/v)[€340m rPFT €470ml CARBIOS **3** Industrial [€260m -1000 rPFT plants €545ml (135kt/v) Current Industrial [€300m -PHA plants danimer €815ml (57kt/v) scientific **Own & Operate** Industrial [€590m -MRIGIN **Bio-PFT** plant €880ml (1,100kt/y) Industrial Industrial Carboxvl [€200m -AFYREN plant plant €250ml ic acids (28kt/v) (28kt/v) Legends Note: (1) As of March 16th, 2022. [min(3-month market cap.)] – max(3-month market cap.)]

peers

Source: public information (investor presentations, company websites)

Avantium's industrial strategy compares favorably to its core

Pilot plants


Flagship plants

Industrial plants

Presentation April 2022

- Avantium's industrial strategy is not an exception - Exact same industrial scale-up pattern observed across all innovative industrial peers (Pilot / Flagship / Industrial)
- ✓ Avantium is actually benefiting from an industrial maturity that compares favorably to other Build & License models
- Avantium industrial phasing designed to mitigate scale-up risks by building a first 5kt FDCA capacity unit as a blueprint for further capacity increase (no scale-up risk associated with larger catalysis units)


Avantium tomorrow: Successfully delivering the next bio chemicals from disruptive technologies



Avantium | Investor

Presentation April

2022



PEF is able to address value-added markets thanks to enhanced performance

🔲 PEF 🔼 PET

Barrier Properties CO2 Oxygen Water **Barrier** Barrier Barrier 10.0x 8.0x 1.0x 1.0x



